Page 80 - MemoriaCIBER-2017ENG

Feagan B G , Sandborn W J , D'Haens G , Panes J , Kaser A , Ferrante M et al Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate- to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study The Lancet 2017;389(10080):1699-1709
47,8310
Zabala-Letona A , Arruabarrena-Aristorena A , Martin-Martin N , Fernandez-Ruiz S , Sutherland J D , Clasquin M et al MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer Nature 2017;547(7661):109-113
40,1370
Forns X , Lee S S , Valdes J , Lens S , Ghalib R , Aguilar H et al Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial The Lancet Infectious Diseases 2017
19,8640
Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M et al Association of Liver Injury From Speci c Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study Gastroenterology 2017;152(5)
18,3920
Egoavil C, Juárez M, Guarinos C, Rodríguez-Soler M, Hernández-Illán E, Alenda C et
al Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their 18,3920 First-Degree Relatives Gastroenterology 2017
Garcia-Pras E , Gallego J , Coch L , Mejias M , Fernandez-Miranda G , Pardal R et al Role and therapeutic potential of vascular stem/ progenitor cells in pathological neovascularisation during chronic portal hypertension Gut 2017
16,6580
CIBEREHD PATENTS 2017 Applied for
• Biomarkers for colorectal cancer (EP 17382267 7)
• Use of ciclopirox as a modulator of the heme group biosynthesis and in the treatment of porphyrias
and other diseases (EP17382371 7)
• Computerized optical analysis methods of MR (magnetic resonance) images for quantifying or
determining liver lesions (JP2017-549070)
• A 3-protein signature to assess prognosis and therapeutic regimen in liver cancer (300257875)
Granted
• Ceria nanoparticles for use in the treatment of hepatocellular carcinoma (EP16163838 2)
• In vitro method for identifying pancreatic cancer or intraductal papillary mucinous neoplasm of
the pancreas (EP16382182 0)
• Plasma microRNAs for the detection of early colorectal cancer (US 15/181,578)
• Bioadhesive platform to perform bioactive treatment (16382365 1 1455)
• Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la croni cación y/o el aclaramiento del virus de la hepatitis c (PCT/ES2016/070115)
80 CIBER ANNUAL REPORT 2017